Segra International is an agriculture-technology firm offering plant tissue culture, genomics, DNA fingerprinting, and pathogen detection services to the cannabis industry. The company produces Verified Clean Stock plantlets from industrial-scale laboratories and claims one of the largest libraries of cannabis cultivars in tissue culture globally. Segra reports it generated revenue in its first eighteen months as a licensed operator and has signed 50 agreements with Canadian and international cannabis companies since the start of 2020. Management says the proprietary technologies help clients mitigate cultivation risk and improve financial performance. The company plans to use new financing to drive continued innovation in plant tissue culture and to expand its sales networks across Canada and around the globe. Segra highlights a multidisciplinary team in agronomy, molecular genetics, plant tissue culture, and regulatory compliance supporting its product and research efforts. Segra International specializes in cannabis plant micropropagation and is developing industrial-scale laboratories in Canada and California to produce disease-free, genetically verified plantlets for licensed producers globally. The company says it has assembled a team with expertise in tissue culture, agronomy, molecular genetics, regulatory compliance, and corporate finance. On July 30, 2018 Segra announced an oversubscribed private placement raising approximately CAD 7.2 million in gross proceeds. Net proceeds will be used for construction of micropropagation facilities, working capital, and general corporate development. Segra structured the offering as Units (each comprising one common share, one-half of a common share purchase warrant, and one liquidity penalty warrant). The company stated an intention to complete a listing on a North American exchange, targeting the Canadian Securities Exchange, on or before October 31, 2018.

Total raised

$10M

Funding rounds

2

Latest round

Equity

Latest activity

Apr 2021